Kynos Therapeutics Emerges From Stealth With £9 Million Financing And Phase 1-Ready Kmo Inhibitor
Apr 07, 2022•over 3 years ago
Amount Raised
£9 Million
Description
Kynos Therapeutics Ltd (Kynos or the Company), an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today emerges from stealth mode with £9 million to finance its lead KMO inhibitor (KMOi) programme through Phase 1 clinical trials and to progress its innovative pipeline of first-in-class KMOi across key indications in inflammation, immunity and metabolism.
FundzWatch™ Score
83
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood